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ABSTRACT 
Rizatriptan Benzoate undergo hepatic first pass metabolism. Aim of present research work is to improve bioavailability by 
formulating in-situ nasal gel. Formulation was developed to decrease the mucociliary authorization by using mucoadhesive polymer 
in gel, thus rising the contact time with nasal mucosa and humanizing the absorption of drug. Gels were primed by cold technique 
process and evaluate by Appearance, Viscosity, Gelation Temperature, Permeation Studies, Drug Content, Gel strength etc.. The 
gelation temperature of all studied gel formulations were found in range.  Drug release was initiated in between 68.8-94.7% with K-
peppas best fit model. pH of gel was in the rang and drug content was found between 92-99.89 %.  Gel strength was found in range 
of 20-55 sec.  
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INTRODUCTION 
The bioavailability of drugs from nasal formulations 
depends on the physicochemical properties of drug and 
formulation that work together to yield optimal drug 
delivery across the membrane. There are certain criteria 
that the drug should satisfy to be distributed optimally 
from the nasal formulation. These are molecular weight, 
lipophilicity, solubility, partition coefficient and pKa. 
Extent of the absorption of the drug depends on 
molecular weight particularly for hydrophilic 
compounds. The absorption of molecules less than 300 
Da may not be influenced by their physicochemical 
properties. Nasal route is suitable for efficient delivery 
of the drugs up to 1000 Da. Absorption reduces 
significantly if the molecular weight is greater than 1000 
Da except with the use of penetration enhancers.  
Lipophilic drugs have been found to be relatively more 
permeable across the nasal epithelium. Drug solubility is 
a major factor in determining absorption of drug through 
biological membranes. As nasal secretions are more 
watery in nature, a drug should have appropriate 
aqueous solubility for increased dissolution
1, 2, 3
. 
The conventional drug delivery systems like solutions, 
suspensions and ointments, emulsions are no longer 
sufficient to fulfill the present day requirements of 
providing a constant rate delivery and prolonged time. 
One of the main reasons for that is poor residence time 
of drug at the site of action, which results into poor 
bioavailability. To overcome this problems gel is the 
dosage form to improve the residence time and 
increased the bioavailability
4
.  
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Gels are defined as a substantially dilute cross-linked 
system, which exhibits no flow when in the steady-state. 
Gel state exists between solid and liquid phase. It has 
properties ranging from soft and weak to hard and 
tough.
 
 
In situ is a Latin word which means in position. In situ 
gel formation is a liquid formulation that generates a 
solid or semisolid depot after administration and shift to 
a gel phase when exposed to physiological conditions. 
This new concept of producing a gel in situ was 
introduced for the first time in the early 1980s. Both 
natural and synthetic polymers can be used for the 
production of in situ gels
5. 6
. 
Carbomer is high molecular weight, cross linked 
polyacrylic acid derivative with a strong mucoadhesive 
property. Carbopol being a pH dependant polymer is 
present in solution form at acidic pH but at alkaline pH 
forms a low viscosity gel.  Carbopol polymers have very 
good water sorption property
7
. They swell in water upto 
1000 times their original volume and 10 times their 
original diameter to form a gel when exposed to a pH 
environment above 4.0-6.0 because the pKa of these 
polymers is 6.0 ± 0.5. 
Rizatriptan benzoate is completely absorbed following 
oral administration. The mean oral absolute 
bioavailability of the Rizatriptan benzoate tablet is about 
45% and means peak plasma concentration (Cmax) 
reaches in approximately 1-1.5 hours (Tmax). The 
presence of a migraine headache did not appear to affect 
the absorption or pharmacokinetics of Rizatriptan 
benzoate. Food has no significant effect on the 
bioavailability of Rizatriptan benzoate but delays the 
time to reach peak concentration by an hour. In clinical 
trials, Rizatriptan benzoate was administered without 
regard to food. The plasma half-life of Rizatriptan 
benzoate in males and females averages 2-3 hours
8-11
. 
Present study is to achieve brain targeted drug delivery 
of rizatriptan benzoate for patients suffering from 
migraine. It is a general study that tries to cover a nose-
to-brain pathway for drug rizatriptan benzoate, 
intranasal delivery, which significantly increases brain 
accumulation of rizatriptan benzoate and could be an 
effective alternative to parentral and oral formulations. 
The nasal ruote will be able to provide longer residence 
properties and hence better bioavailability of the drug. 
Formulation in the nasal cavity exhibited prolonged 
drug release characteristics with almost negligible toxic 
effects to the nasal mucosa. The ease of administration 
coupled with its ability to provide sustained release 
could probably result in less frequent administration, 
thus enhancing patient compliance. 
MATERIALS AND METHOD 
Rizatriptan Benzoate was obtained from M/s Torrent 
Pharmaceuticals Pvt. Ltd., Other chemicals and 
instruments were used analytical grade. 
METHODS 
Preparation of gels 
Nasal gels were prepared using bioadhesive polymers at 
its optimum concentrations as determined by 
viscometric studies. The materials were dissolved in a 
measured volume of nasal solution. The insides were 
sonicated using Pci Ultrasonic cleaner for 10 min and 
stirred in a magnetic stirrer for 15 min. The whole 
substance was sealed and stored in the refrigerator 
overnight to allow complete swelling. An aliquot 
amount of Rizatriptan Benzoate was added and stirred 
again for 15 min. The prepared gel was sonicated to 
ensure the complete removal of air bubbles. Similarly 
gels were prepared using different enhancers. 
 
Table 1: Formulation of in-situ nasal gel of Rizatriptan Benzoate 
Composition (%(w/v)) Rizatriptan Benzoate Pluronic F127 Carbopol 934P 
Batch Code 
F1 2.5 18 - 
F2 2.5 18 0.1 
F3 2.5 18 0.2 
F4 2.5 18 0.3 
F5 2.5 18 0.4 
F6 2.5 18 0.5 
 
Evaluation of Gels 
Appearance 
The developed formulations were inspected visually for 
clarity in sol and gel form. 
pH of the gels 
The pH of the formulations was gritty by bring the 
electrode of the pH meter in contact with the surface of 
the formulation and allowing it to equilibrate for 1min
12, 
13
. 
Gelation Studies 
The in situ gel forming solution and the artificial nasal 
fluid were mixed and the gelation was observed by 
visual examination. Gelation studies were carried out 
according to (Balasubhramanian J. et al 2003)
14 
in 
different pH Buffers (pH5.0, 6.0, 6.6, 7.4) and was 
assessed by visual examination. Gelation temperature 
and gel melting was assessed by a modified process
15   
as 
follow 2 ml aliquot of gel was transferred to test tube, 
sealed with aluminium foil and increased in increment 
of 1
0
C and left to equilibrate for 5 min at each new 
setting. The samples were then examined for gelation 
which was said to have occurred when meniscus no 
longer move upon tilting through 90
0
C. The gel melting 
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temperature, a critical temperature when the gel starts 
flowing upon tilting 
  
90
0
C, was recorded. 
Content uniformity 
Formulations were tested for content uniformity. Bottles 
containing the formulation were properly shaken for 2.3 
min. The formulation, 1.0 ml was transferred into a 100-
ml volumetric flask and 50 ml of simulated nasal fluid 
was added. The formed gel was completely crushed with 
the help of a glass rod, followed by vigorous shaking 
until the formed gel got completely dispersed to give a 
clear solution. The volume was adjusted to 100 ml with 
simulated tear fluid. The solution was filtered through a 
0.45-mm filter membrane and the drug concentration 
was determined with a UV-Visible spectrophotometer at 
280 nm
16, 17
.
 
Determination of Mucoadhesive Strength 
Mucoadhesive Strengths of gel was determined by using 
the modified method reported by Choi et al
18
. Nasal 
mucosal tissues, obtained from the local slaughterhouse, 
were carefully removed from the nasal cavity of goat 
and mounted on glass surface using adhesive tape while 
another mucosal section was fixed in inverted position 
to the cylinder. 50mg of gel was placed on mucosal 
surface. The glass mounted mucosal surface with gel 
formulation and mucosal surface attached to cylinder 
were held in contact with each other for 2min to ensure 
intimate contact between them. In second pan, the 
weights were kept rising until two mucosa get detached 
from each other. The nasal mucosa was changed for 
each measurement 
 Viscosity Measurement  
The viscosity measurements were carried out by using 
Brookfield DV Pro-II model with spindle No.62.The 
instrument was equipped with the temperature control 
unit and the sample were equilibrated for 10 min before 
the measurement. The viscocity was measured against 
increasing shear rate. Measurement was taken at 4
0
c and 
34
0 
c respectively
19
.
 
In-vitro Release Studies 
 The drug release of the Rizatriptan Benzoate in situ gel 
was measured using Franz diffusion cell. Assembly was 
set and the temperature was maintained at 37±0.5°C, 
then 2 ml of nasal in situ gel of Rizatriptan Benzoate in 
was applied in the donor compartment, which was 
separated by the receptor compartment with the 
cellophane membrane. Three ml aliquots of samples 
were withdrawn at regular time intervals and replaced 
with an equal volume of phosphate buffer as fresh 
receptor medium. The samples were appropriately 
diluted with Phosphate buffer and analyzed 
spectrophotometrically (Double beam UV-visible 
spectrophotometer) at 280 nm
20
.
 
Drug release kinetics and mechanism:  
In order to understand the kinetic and mechanism of 
drug release, the result of in vitro drug release study of 
nasal in situ gels were fitted with various mathematical 
models. Based on the R2-value or n-value, the best-
fitted model was selected
21,22
. 
Drug content estimation 
Each formulation (1 ml) was taken in a 100 ml 
volumetric flask diluted with distilled water and shaken 
to dissolve the drug. The solution was filtered through 
whatmann filter paper and 1ml of filtered solution was 
further diluted to 100 ml with distilled water. Drug 
content was estimated spectrophotometrically by 
measuring the absorbance of the above solution at 280 
nm
23, 24
. 
RESULTS AND DISCUSSION 
Mucoadhesive Polymer Formulations 
Mucoadhesive dosage forms have gained and still 
gaining, considerable interest as a means of providing 
intimate contact and prolonging the residence time of a 
dosage form intended for nasal and ocular 
administration  
It generally accepted that process involves three steps; 
wetting and swelling of the polymer to permit intimate 
contact with biological tissue, interpenetration of 
bioadhesive polymer chains with mucin molecules 
leading to entanglement and formation of weak 
chemical bonds between entangled chains, the 
mechanisms by which mucoadhesion bonds form are not 
completely clear. There are five theories of adhesion 
have been developed to explain the properties of wide 
range of materials including glues, adhesives and paint. 
Evaluations of Gels 
Appearance 
Table 2: Appearance of gel 
S.NO. Formulation Code Appearance 
1 C1 Transparent solution 
2 C2 Transparent &Viscous solution 
3 C3 Transparent solution 
4 C4 Transparent solution 
5 C5 Transparent solution 
6 C6 Transparent &Viscous solution 
 
Clarity of all the formulations was found to be 
satisfactory. 
pH of mucoadhesive nasal gels 
The pH of the formulations was found to be satisfactory 
and was in the range of 4.5-5.5. 
Gelation Temperature  
It was previously proved that pluronics undergo thermal 
gelation or sol-gel transition at a temperature of about 
25 to 37°C. Below the transition temperature Pluronic 
solutions allow a comfortable and precise delivery in the 
nasal cavity where thermogelation occurs. Immediate 
gelling increases residence time and enhances 
bioavailability of drug. The gelation temperature of all 
batches is shown in table 3. In Pluronic gels, gelation 
studies in 20-24 %( w/w) concentration showed that 
gelation temperature decreases with increase in gel 
melting temperature as Pluronic concentration increases. 
Gelation of PF-127 was found dependent on aqueous 
solubility of the polymer.  
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Table 3: Gelation Temperature 
S.No. Formulation Gelation Temp. 
1 F1  42
0
c  
2 F2  38
0 
c  
3 F3  32
0 
c  
4 F4  36
0 
c  
5 F5  38
0 
c  
6 F6  40
0 
c  
 
Viscosity: Viscosity measurement of the formulations at 
4
0
c and 37
0
c temperatures showed that there was 
increase in viscosity with increase in temperature. This 
indicated the formation of temperature induced gel 
structure of poloxamer.in addition to this Carbopol 934 
showed viscosity enhancing effect. At constant 
concentration, abrupt changes in viscosities were 
observed due to sudden rise in micellar concentration. 
At low temperature region the liquid shows a very slight 
decrease in viscosity which was attributed to the 
dehydration of PPO blocks of the unimers .with rise in 
temperature. The unimers start to form spherical 
micelles causing increase in intrinsic viscosity as a 
result of extremely high salvation in the micellar shell. 
At 1◦ C temperature increase causes 10% increase in the 
micellar concentration and 3.3% decrease in the 
intermicellar distance as well as two-fold increase in 
viscosity. Viscosity of all formulation at 4
0
c and 37
0 
c 
showed in table  
 
Table 4: shows measurement of viscosity 
S.NO Formulation Viscosity (CP) at 4
0 
C Viscosity (CP) at 37
0 
C 
1 F1 23.4 144 
2 F2 33 947 
3 F3 42.3 2879 
4 F4 51.3 164000 
5 F5 27.3 287.9 
6 F6 36.9 1236 
 
Measurement of gel strength 
It is very important that the nasal gel formulation must 
have suitable gel strength. The gel strength of nasal gel 
formulation at 37
o 
C, increased as the concentration of 
Carbopol and Poloxamers increased The mechanism of the 
increase gel strength might be related to hydrogen bonding 
between Pluronic and bioadhesive polymers in the nasal 
gel.  
 
Table 5: Measurement of Gel Strength 
S.N. Formulation Gel strength in Sec Bioadhesive Force (Dynes/cm
2
) 
1 F1 110 2496.81±10 
2 F2 117 4369.42±0.113 
3 F3 130 8114.64±0.118 
4 F4 115 2746.49±0.11 
5 F5 120 3745.22±0.12 
6 F6 118 2496.81±0.12 
 
Mucoadhesive strength was determined in term of 
detachment stress i.e. force required to detach the 
formulation from mucosal surface. Results indicated that 
the variation in concentration of Carbopol 934 and 
Poloxamers 407 showed changes in Mucoadhesive 
strength. The gradual increase was observed in 
Mucoadhesive strength as the level of Carbopol 934 
increased .Our findings are similar with previously reported 
work with Carbopol polymer. In this review, bioadhesion 
was observed due to the availability of carboxyl group. 
Carbopol has very high percentage of (58%-68%) of 
carboxyl group that undergoes hydrogen bonding with 
sugar residues in oligosaccharide chain in mucus 
membrane, resulting in strengthened network between 
polymer and mucus membrane. The stronger the 
Mucoadhesive force is, the more it can prevent the gelled 
solution coming out of the nose. 
 
Table 6: Gelling Capacity and Drug Content 
S.No pH Gelling Capacity Drug Content 
F1 4.2 ++ 98.01±0.83 
F2 4.5 +++ 97.19±0.92 
F3 5.0 + 98.51±0.13 
F4 4.2 ++ 97.26±0.12 
F5 5.5 +++ 96.54±0.98 
F6 4.8 +++ 98.04±0.18 
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Drug content uniformity determination 
The percent drug content for formulations F7 to F11. 
The drug content was found to be in acceptable range 
for all the formulations. Percent drug content of 
formulations F7, F8, F9, F10 and F11 was found to be 
91.80%, 98.33%, 99.19%, 97.03% and 94.09% 
respectively. This indicates that process employed to 
prepare gels in this study was capable of producing gels 
with uniform drug content and minimal gel variability. 
Drug Release 
Diffusion studies were carrying out using franz diffusion 
cell, F5 showed the persistent drug release. F3 showed 
drug release 79.76% at 8hrs. Concentration of HPMC 
raise leads to decrease the drug release. Poloxamer 
concentration distress on drug release. 
 
Table 7: Cumulative Drug Release 
Time (min) % CDR F1 % CDR F2 % CDR F3 
 
 
% CDR F4 % CDR F5 % CDR F6 
0 0 0 0 0 0 0 
15 12.13 14.935 15.217 10.456 9.562 10.9934 
30 16.85 18.1264 16.6659 13.006 12.0156 13.001 
45 22.56 21.6749 21.4845 16.002 14.2212 15.5397 
60 28.57 28.123 25.75339 20.5432 17.1237 18.3132 
90 30.26 30.9835 30.3671 23.728 24.8414 21.8782 
120 36.57 39.2554 35.2461 29.123 29.3833 26.2274 
180 38.12 45.07651 41.4426 32.747 37.012 30.5667 
240 43.46 54.132 47.3362 38.4563 38.3215 35.2564 
300 63.5623 81.8279 67.779 58.8701 54.7415 54.45616 
360 69.12 83.125 74.1256 68.4589 64.9871 63.1456 
420 44.4562 88.125  77.5045 72.1207 68.459 
480  91.456  86.1829 81.002 77.5947 
 
Figure 1: Drug Release Kinetics Zero Order Formulation 
(F1) 
 
 
Figure 2: Drug Release Kinetics First Order Formulation 
(F1) 
 
Figure 3: Drug Release Kinetics Higuchi Formulation (F1) 
 
 
Figure 4: Drug Release Kinetics Kors - Peppas 
Formulation (F1) 
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Figure 5: Drug Release Kinetics Zero Order Formulation 
(F2) 
 
 
Figure 6:  Drug Release Kinetics First Order Formulation 
(F2) 
 
 
Figure 7: Drug Release Kinetics Higuchi Formulation (F2) 
 
 
Figure 8: Drug Release Kinetics Kors-Peppas Formulation 
(F2) 
 
Figure 9: Drug Release Kinetics Zero Order Formulation 
(F3) 
 
 
Figure 10: Drug Release Kinetics First Order Formulation 
(F3) 
 
 
Figure 11: Drug Release Kinetics Higuchi Formulation 
(F3) 
 
 
Figure 12: Drug Release Kinetics Kors-Peppas 
Formulation (F3) 
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Figure 13: Drug Release Kinetics Zero Order Formulation 
(F4) 
 
 
Figure 14: Drug Release Kinetics First Order Formulation 
(F4) 
 
 
Figure 15: Drug Release Kinetics Higuchi Formulation 
(F4) 
 
 
Figure 16: Drug Release Kinetics Kors - Peppas 
Formulation (F4) 
 
Figure 17: Drug Release Kinetics Zero Order Formulation 
(F5) 
 
 
Figure 18: Drug Release Kinetics First Order Formulation 
(F5) 
 
 
Figure 19: Drug Release Kinetics Higuchi Formulation 
(F5) 
 
 
Figure 20: Drug Release Kinetics Kors- Peppas 
Formulation (F5) 
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Figure 21: Drug Release Kinetics Zero Order Formulation 
(F6) 
 
 
Figure 22: Drug Release Kinetics First Order Formulation 
(F6) 
 
 
Figure 23: Drug Release Kinetics Higuchi Formulation 
(F6) 
 
 
Figure 24: Drug Release Kinetics Kors-Peppas 
Formulation (F6) 
 
Permeation study 
In vitro permeation study 
 
Permeation of selected batch (F2) compare to drug 
solution. 
Ex vivo permeation carried out by using nasal mucosa 
of goat and permeation profile shown in the above 
figure. 
Stability studies 
All the formulation showed good stability at 27 °C/ 60 
% RH. There were no significant changes in visual 
appearance and clarity; pH remained constant for entire 
stability period; drug content did not deviate by than 2% 
indicating that the drug is stable in the in situ gel 
formulations and also there was no significant variation 
in the in vitro release studies at the end of 30 day period. 
A formulation intended for a nasal administration, if 
prepared as a solution should not show precipitation of 
the drug present in it for long periods of storage. This is 
achieved when formulations were stored at normal room 
temperatures not exceeding 32 °C. The formulation 
when stored under refrigerated conditions showed 
settling of the polymer and also the viscosity of the 
formulation increased. The formulations when stored at 
45 °C/ 75 % RH, the formulations remained as a gel for 
long duration. 
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